A Phase 1/2 interventional study of Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) in EBV-induced Lymphomas, EBV-associated Malignancies and Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma, sponsored by Atara Biotherapeutics. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2023-02-13.
Sponsored by Atara Biotherapeutics · Phase 1/2, Interventional, and Treatment
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
This study's enrollment of 58 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Atara Biotherapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
It is expected that five types of patients afflicted with EBV-associated lymphomas or lymphoproliferative diseases will be referred and will consent to participate in this trial. These are:
Exclusion Criteria:
The following patients will be excluded from this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) following hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel (tab-cel) at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ PTLD following solid organ transplant (SOT) who were R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ following PTLD HCT who were R/R to rituximab or rituximab naive will receive IV infusion of transplant donor-derived EBV-cytotoxic T lymphocytes (CTLs) at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ PTLD following SOT who were R/R to rituximab and chemotherapy will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ viremia will receive IV infusion of transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel or transplant donor-derived EBV- CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel or transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
Also known as: tabelecleucel (tab-cel®, ATA129), allogeneic EBV-CTLs, transplant donor-derived EBV-CTLs
Objective Response Rate (ORR)
The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel; and PR is a 50 % or greater reduction in the size of all lymphomatous lesions as determined by computed tomography (CT) or magnetic resonance imaging (MRI) measurements of tumor volume, which was maintained for at least 3 weeks following completion of a cycle of tabelecleucel. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR is clearance of EBV without subsequent development of EBV+ LPD; and PR is at least a 10-fold decrease in EBV DNA levels.
Time frame: From Day 1 through 251.1 months after Day 1 dose
Overall Survival (OS)
The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.
Time frame: From Day 1 through 251.1 months after Day 1 dose
OS Rate at 12 Months
Percentage of participants with OS at 12 months are reported. The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.
Time frame: From Day 1 through 12 months after Day 1 dose
OS Follow-up Time
The OS at follow-up time are reported. The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.
Time frame: From Day 1 through 251.1 months after Day 1 dose
Time to Response (TTR)
The TTR was defined as the time from the date of the first dose of tabelecleucel or EBV-CTLs to the date of a PR or CR, whichever occurred first. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR was defined as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs; and a PR was defined as a 50 % or greater reduction in the size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, which was maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR was defined as clearance of EBV without subsequent development of EBV+ LPD; and PR was defined as at least a 10-fold decrease in EBV DNA levels.
Time frame: From Day 1 through 251.1 months after Day 1 dose
Clinical Benefit Rate (CBR)
The CBR was the proportion of participants who have achieved a CR, PR or SD assessed at least 28 days after first dose date of study drug. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBVCTLs; and a PR as a \>= 50% reduction in size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR as clearance of EBV without subsequent development of EBV+ LPD; and PR as at least a 10-fold decrease in EBV DNA levels. The CBR was included specifically as clinically meaningful for solid tumor, namely LMS.
Time frame: From Day 1 through 251.1 months after Day 1 dose
| Milestone | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ AID-LPD (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ NPC (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) | EBV+PID-LPD (Tab-cel or EBV-CTLs Only) | EBV+ Lymphoma (Tab-cel or EBV-CTLs Only) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 11 | 4 | 2 | 5 | 1 | 23 | 2 | 6 | 2 | 2 |
| Completed | 4 | 2 | 1 | 3 | 0 | 8 | 1 | 4 | 0 | 0 |
| Not completed | 7 | 2 | 1 | 2 | 1 | 15 | 1 | 2 | 2 | 2 |
| Withdrew: Death | 4 | 1 | 1 | 0 | 0 | 13 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel; and PR is a 50 % or greater reduction in the size of all lymphomatous lesions as determined by computed tomography (CT) or magnetic resonance imaging (MRI) measurements of tumor volume, which was maintained for at least 3 weeks following completion of a cycle of tabelecleucel. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR is clearance of EBV without subsequent development of EBV+ LPD; and PR is at least a 10-fold decrease in EBV DNA levels.
| Percentage of participants | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 63.6 (30.8 to 89.1) | 50.0 (6.8 to 93.2) | 0 (0 to 52.2) | 43.5 (23.2 to 65.5) | 57.1 (18.4 to 90.1) |
The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.
| Months | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) |
|---|---|---|---|---|---|
| Overall Survival (OS) | 14.8 (0.9 to NA) | 84.8 (1.1 to 115.0) | NA (60.6 to NA) | 18.6 (1.5 to NA) | NA (2.5 to NA) |
Percentage of participants with OS at 12 months are reported. The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.
| Percentage of participants | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) |
|---|---|---|---|---|---|
| OS Rate at 12 Months | 54.5 (22.9 to 78.0) | 75.0 (12.8 to 96.1) | 100.0 (100 to 100) | 52.2 (30.5 to 70.0) | 85.7 (33.4 to 97.9) |
The OS at follow-up time are reported. The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.
| Months | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) |
|---|---|---|---|---|---|
| OS Follow-up Time | 14.82 (0.5 to 88.9) | 63.56 (1.1 to 115.0) | 77.40 (29.5 to 109.3) | 18.63 (0.2 to 251.1) | 62.98 (2.5 to 91.3) |
The TTR was defined as the time from the date of the first dose of tabelecleucel or EBV-CTLs to the date of a PR or CR, whichever occurred first. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR was defined as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs; and a PR was defined as a 50 % or greater reduction in the size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, which was maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR was defined as clearance of EBV without subsequent development of EBV+ LPD; and PR was defined as at least a 10-fold decrease in EBV DNA levels.
| Months | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) |
|---|---|---|---|---|---|
| Time to Response (TTR) | 1.18 (0.8 to 2.4) | 6.74 (3.1 to 10.4) | — | 1.45 (0.6 to 5.1) | 1.22 (1.1 to 1.4) |
The CBR was the proportion of participants who have achieved a CR, PR or SD assessed at least 28 days after first dose date of study drug. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBVCTLs; and a PR as a \>= 50% reduction in size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR as clearance of EBV without subsequent development of EBV+ LPD; and PR as at least a 10-fold decrease in EBV DNA levels. The CBR was included specifically as clinically meaningful for solid tumor, namely LMS.
| Percentage of participants | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) |
|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 63.6 (30.8 to 89.1) | 75.0 (19.4 to 99.4) | 80.0 (28.4 to 99.5) | 47.8 (26.8 to 69.4) | 71.4 (29.0 to 96.3) |
Collected over From Day 1 through 251.1 months after Day 1 dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall Total | 32/58 (55.2%) | 40/58 (69%) | — |
| Event | Overall Total |
|---|---|
| PyrexiaGeneral disorders | 13/58 |
| Device related infectionInfections and infestations | 8/58 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 5/58 |
| InfectionInfections and infestations | 4/58 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/58 |
| Abdominal painGastrointestinal disorders | 3/58 |
| Disease progressionGeneral disorders | 3/58 |
| Neutropenic infectionInfections and infestations | 3/58 |
| DehydrationMetabolism and nutrition disorders | 3/58 |
| SeizureNervous system disorders | 3/58 |
Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Results from arms with \<= 3 participants (as shown in the participant flow) are being excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.
| Age, Customized(Participants) | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) | Total |
|---|---|---|---|---|---|---|
| <18 years | 7 | 3 | 4 | 8 | 3 | 25 |
| =>18 years | 4 | 1 | 1 | 15 | 4 | 25 |
| Sex: Female, Male(Participants) | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 1 | 2 | 7 | 2 | 19 |
| Male | 4 | 3 | 3 | 16 | 5 | 31 |
| Ethnicity (NIH/OMB)(Participants) | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 | 1 | 5 |
| Not Hispanic or Latino | 1 | 1 | 0 | 4 | 1 | 7 |
| Unknown or Not Reported | 10 | 3 | 3 | 17 | 5 | 38 |
| Race (NIH/OMB)(Participants) | EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only) | EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only) | EBV+ LMS (Tab-cel Only) | EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only) | EBV+ Viremia (EBV-CTLs Only) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 0 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 2 | 1 | 6 |
| White | 6 | 1 | 3 | 18 | 5 | 33 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 1 | 2 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atara Biotherapeutics